Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.07
(
-0.58%
)
Bitcoin
74,294.00
(
0.48%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 100784

Thursday, 08/05/2010 2:03:11 PM

Thursday, August 05, 2010 2:03:11 PM

Post# of 257253
Does anyone here care to comment on Xarelto? It’s a potentially consequential drug for several companies—not just for JNJ and Bayer—and it’s an especially hard program to handicap, IMO.

Here are a few posts for background reading in case anyone is interested:

#msg-38200098 FDA issues CRL (no response submitted yet)
#msg-44245112 Safety signal in EINSTEIN-EXT study
#msg-34103973 Phase-3 data in VTE prevention
#msg-39151366 Xarelto prospects in ACS

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now